Peri-implantitis is becoming increasingly difficult to describe solely as a local complication around an implant. Bacterial biofilm remains a key factor initiating inflammation, but the course of the disease may be modified by the patient’s systemic health, metabolism, chronic diseases, and immune response profile. Diabetes, obesity, metabolic syndrome, cardiovascular disease, osteoporosis, and autoimmune disorders do not always act as direct causes of peri-implantitis. However, they may create a biological environment in which inflammation around an implant develops more rapidly, is more difficult to resolve, and is more likely to lead to bone loss.
For many years, implant dentistry has been associated mainly with surgery, prosthetics, and the assessment of local bone conditions. In clinical practice, these elements remain fundamental: bone quantity and quality, implant position, primary stability, prosthetic design, oral hygiene, and regular supportive care. However, the long-term maintenance of an implant depends not only on the local success of the procedure. Increasingly, it also depends on the organism in which the implant will function over the following years.
An implant patient is not simply a patient with a missing tooth. Each patient has a specific medical history, metabolism, immune response, lifestyle, and potential inflammatory burden. In some patients, the body effectively controls local inflammatory stimuli. In others, even a comparable level of biofilm or similar clinical conditions may lead to a more intense and more difficult-to-control reaction. This is why peri-implantitis is increasingly analyzed as a multifactorial disease developing at the intersection of biofilm, host response, local factors, and systemic conditions.
In the PERI-EDU project materials, systemic diseases are presented precisely in this way: not as a simple list of contraindications to implant treatment, but as elements of a broader risk profile. Cardiovascular disease, diabetes, obesity, metabolic syndrome, osteoporosis, autoimmune disorders, and thyroid disease may influence the course of inflammation, healing, bone metabolism, microcirculation, and immune response. Their relevance, however, depends on disease control, coexisting risk factors, lifestyle, and the patient’s periodontal history.
One of the best-described examples is diabetes, especially poorly controlled type 2 diabetes. Hyperglycemia may promote oxidative stress, the formation of advanced glycation end products, impaired collagen turnover, reduced angiogenesis, and delayed wound healing. In practice, this may mean greater tissue susceptibility to chronic inflammation, deeper pockets, increased marginal bone loss, and more difficult osseointegration in cases additionally burdened by other risk factors.
This does not mean, however, that every patient with diabetes is automatically at high risk of implant loss. What matters most is the level of metabolic control and the coexistence of other factors: smoking, previous periodontal disease, dyslipidemia, obesity, or insufficient supportive care. This distinction is clinically important because it allows clinicians to move away from simple patient labeling and toward individualized risk assessment.
Cardiovascular diseases should be viewed in a similar way. Available studies suggest a weak-to-moderate association between cardiovascular disease and peri-implantitis, and this relationship often becomes less robust after behavioral, metabolic, and systemic confounders are taken into account. In practice, cardiovascular disease is better understood as part of a broader inflammatory and metabolic profile than as an independent, direct cause of peri-implant tissue disease.
The biological rationale behind this relationship is nevertheless important. Patients with cardiovascular disease often present elevated levels of inflammatory mediators such as CRP, IL-6, and TNF-α. The same mediators are involved in processes related to osteoclast activation, soft tissue damage, and bone loss around implants. When dyslipidemia, endothelial dysfunction, impaired microcirculation, diabetes, or smoking are also present, the biological environment around the implant may become less favorable for long-term stability.
Another area of particular importance for implant dentistry is obesity and metabolic syndrome. The issue is not merely body weight as a numerical parameter, but the chronic low-grade inflammatory state that may accompany metabolic disorders. Adipose tissue, especially visceral fat, is an active immunometabolic organ. It may contribute to persistently elevated levels of pro-inflammatory cytokines, altered neutrophil and macrophage function, increased oxidative stress, and changes in healing and bone metabolism.
From this perspective, a patient with metabolic syndrome is not only a generally medically burdened patient. They may be a patient in whom the response to local biofilm around an implant occurs in the context of pre-existing inflammatory activation. This may influence the frequency and severity of peri-implant inflammation, especially when diabetes, dyslipidemia, cardiovascular disease, poor oral hygiene, or a history of periodontitis are also present.
Osteoporosis illustrates another aspect of the same problem: the importance of bone quality and bone remodeling. Reduced bone mineral density, altered bone turnover, and a pro-resorptive background may influence implant prognosis. At the same time, the literature is not entirely consistent, and interpretation is complicated by factors such as antiresorptive therapy, the indications for its use, dosage, route of administration, and the patient’s overall risk profile. Therefore, osteoporosis should not be treated as an automatic exclusion from implant therapy, but as a factor requiring careful assessment, planning, and monitoring.
Autoimmune diseases are even more complex. They may be associated with chronic activation of the immune system, dysregulated cytokine production, and altered tissue healing. In some cases, they may also complicate diagnosis, because mucosal lesions, ulcers, medication-related adverse effects, or immune-mediated processes may resemble or mask the classical symptoms of infectious peri-implant inflammation. In such situations, a simple diagnosis of “peri-implantitis” may not be sufficient; broader medical and dental assessment is needed.
The common denominator of many chronic diseases is chronic inflammation, impaired resolution of the immune response, or unfavorable changes in tissue metabolism. This is why the PERI-EDU project draws attention to the axis linking peri-implantitis, systemic inflammation, and systemic diseases. Biofilm remains the main etiological factor in peri-implant tissue inflammation, but its impact may be amplified by host susceptibility, dysbiosis, metabolic disease, genetic factors, smoking, or other systemic burdens.
For clinicians, however, the most important issue is not the mere existence of these associations, but their diagnostic and organizational consequences. A general medical history in an implant patient should not be treated as a formality. Information about diabetes, glycemic control, cardiovascular disease, medication use, osteoporosis, antiresorptive therapy, autoimmune disorders, obesity, smoking, or previous periodontal disease may be relevant both for treatment planning and long-term follow-up.
This does not mean that every patient with a chronic disease should be excluded from implant therapy. On the contrary, modern implant dentistry increasingly relies on informed qualification, risk factor control, and individualized care. In one patient, a standard maintenance protocol may be sufficient. In another, closer cooperation with the patient’s physician, more intensive periodontal support, shorter recall intervals, earlier diagnosis of inflammation, or more cautious prosthetic decisions may be required.
A previous history of periodontitis is especially important. Prior periodontal disease is one of the strongest and most reproducible risk indicators for peri-implantitis. A patient who lost teeth due to periodontal disease does not become biologically “new” after implants are placed. They may still have susceptibility to dysbiosis, an excessive inflammatory response, loss of supporting tissues, and the need for long-term supportive therapy.
This is where interest in inflammatory markers and indices becomes particularly relevant. If chronic diseases may modify the response around implants, and peri-implantitis may be part of a broader systemic profile, it is reasonable to ask whether blood tests could support patient assessment. Not as a substitute for clinical examination, but as a potential complement to the overall risk picture.
Classical markers such as CRP, IL-6, TNF-α, and leukocyte count may indicate inflammatory activity, but they are nonspecific. They may change in infection, trauma, chronic disease, inflammatory stress, or as a result of pharmacotherapy. For this reason, the PERI-EDU project also analyzes aggregated inflammatory indices derived from blood count parameters, which may better reflect relationships between different elements of the immune response.
At this stage, however, caution is essential. Inflammatory indices are not standalone diagnostic tests for peri-implantitis. They do not replace probing, assessment of bleeding, measurement of pocket depth, radiological analysis, or prosthetic evaluation. In the future, however, they may help improve risk stratification, patient monitoring, and our understanding of why the disease progresses faster or responds less favorably to treatment in some individuals.
The significance of systemic diseases in peri-implantitis is therefore not based on a simple statement that “disease X causes implant loss.” Such a message would be too simplistic. It is more appropriate to think of the patient as a biological system in which local inflammation around the implant meets systemic immunity, metabolism, microcirculation, bone status, and healing capacity. This interaction may be stable and favorable, but it may also promote disease progression.
The PERI-EDU project follows this direction of thinking. Its aim is not only to describe peri-implantitis as a local disease of peri-implant tissues, but also to better understand how immune response and systemic inflammation may influence its course. For academic education, this means that implant dentistry should not be taught only as a surgical and prosthetic procedure, but as a treatment that requires understanding the biology of the patient.
For clinical practice, the conclusion is simple, although demanding: a patient with an implant should be assessed more broadly than the implant itself. Biofilm must be controlled, prosthetic design must be appropriate, and tissues must be monitored regularly. But it is equally important to understand whether the patient’s organism supports the resolution of inflammation, or instead maintains and amplifies it.
The implant patient is therefore a systemic patient. The better we understand their inflammatory, metabolic, and immunological profile, the greater the chance of making more informed decisions, detecting problems earlier, and achieving long-term stability in implant treatment.